Kaname Nosaki
Kashiwa, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation.
Journal: Cancer treatment and research communications
Published: August 12, 2025
Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry.
Journal: JTO clinical and research reports
Published: January 23, 2025
Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 13, 2025
A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score).
Journal: Future oncology (London, England)
Published: December 30, 2024
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.
Journal: Current problems in cancer
Published: November 08, 2024
Protocol summary of a randomized phase III study: comparing systemic therapy with and without debulking surgery (primary tumour resection) for clinical stage IVA (cT1-2bN0-1M1a) non-small cell lung cancer with radiologically undetermined pleural dissemination JCOG2103 (DEBULK-LUNG).
Journal: Japanese journal of clinical oncology
Published: August 14, 2024
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 11, 2024
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50].
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 18, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 24, 2024
Efficacy and safety of upfront radiotherapy with immune checkpoint inhibitors for brain metastasis in non-small cell lung cancer.
Journal: Cancer treatment and research communications
Published: April 21, 2024
Unrealistic expectations and disclosure of incurability in patients with non-small cell lung cancer.
Unrealistic expectations and disclosure of incurability in patients with non-small cell lung cancer.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: March 26, 2024
Last Updated: 09/26/2026